(In thousands, except per-share amounts)
CompanySymbol/Revenues / ProfitsPershareR & D/Cash Shares
Period% changeCurrent/compCurrent/comp% Changeor Equiv.
Allergan Ligand Retinoid*ALRIZ/403/NA(8,000)/NA(2.46)/NA8,100NA94,300NR
Alpha-BetaABTI/2Q478/14%(6,330)/(5,375)(0.54)/(0.46)4,82911%29,91411,687
Aprogenex**APG/2Q8/(1,438)/(3,406)(0.29)/(0.72)960-64%3,6434,994
ArgusARGS/2Q300/95%(3,952)/(4,557)(0.18)/(0.24)1,760-12%3,19710,582
BioChem Pharma***BCHXF/2Q44,985/53%(2,348)/(922)(0.05)/(0.02)5,42525%46,31548,819
Celgene#CELG/2Q404/-46%(2,300)/(2,000)(0.29)/(0.26)NRNR16,000NR
CollagenCGEN/4Q20,226/8%2,700/1,6310.29/0.172,67212%9,3849,250
DNA PlantDNAP/2Q3,558/-18%(3,981)/(6,858)(0.15)/(0.27)1,455-19%1,36231,520
ESCAgenetics##ESNG/1Q10/-97%(645)/(1,824)(0.09)/(0.26)0-100%2207,343
Houston BiotechnologyHBI/2Q24/-82%(674)/(980)(0.12)/(0.20)496-43%9145,639
InnovirINVR/3Q38/23%(1,344)/(981)(0.37)/(0.31)70025%3,3003,589
Interferon SciencesIFSC/2Q452/445%(1,540)/(2,572)(0.07)/(0.13)NRNRNR22,464
Ligand###LGND/2Q5,354/117%(41,544)/(7,359)(1.87)/(0.44)9,06539%72,42122,180
NeurogenNRGN/2Q15,870/1280%12,234/(1,588)1.10/(0.18)NRNR29,94411,172
Neurological Tech.NTII/4Q147/-5%(1,463)/(1,067)(0.37)/(0.27)1,25548%8,7523,935
Protein Design LabsPDLI/2Q4,061/-12%(2,438)/(200)(0.16)/(0.01)5,30242%110,09315,338
Sheffield MedicalSHM/2Q12/-63%(1,882)/(1,300)(0.25)/(0.19)1,04585%NR7,647
XomaXOMA/2Q16/-99%(7,477)/(7,254)(0.33)/(0.33)NRNR27,10022,438
ZonagenZONA/2Q699/1605%(963)/(941)(0.25)/(0.25)591-17%7453,839
ZynaxisZNXS/2Q50/-86%(1,014)/(2,454)(0.19)/(0.47)1,717-3%1,6845,264
NOTES:
NA = Not Available
NR = Not Reported
All NASDAQ except Aprogenex (AMEX), HoustonBiotechnology (AMEX) and Sheffield Medical (AMEX).
* Allergan Ligand Retinoid Therapeutics went public inJune.
** Aprogenex had no revenue in comparable 1994quarter.
*** BioChem Pharma's numbers are in Canadian dollars.
# Celgene's numbers include $12 million raised after thequarter ended.
## ESCAgenetics had research and developmentexpenses of $1.6 million in comparable 1994 quarter.
### Ligand's net loss includes $37.4 million in chargesrelated to the Glycomed acquisition and formation ofAllergan Ligand Retinoid Therapeutics.
(c) 1997 American Health Consultants. All rights reserved.